Carly R. Cabel

This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.

This study identifies P2RX7 as a key regulator of Treg suppressive function in lung tumors, showing that targeting P2RX7 could improve lung cancer treatment by reducing Treg-mediated immune suppression.

This paper designs and evaluates Dyr726, a brain-penetrant multi-kinase inhibitor that targets PI3Kα, receptor tyrosine kinases, and WNT signaling, showing efficacy in preclinical cancer models.

The paper identifies and validates small molecule and natural product inhibitors targeting the VEGF-A/NRP-1 interaction, with potential applications in treating neuropathic pain, cancer, and SARS-CoV-2 infection.